PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33969575-0	2021	Amplification of DDR2 mediates Sorafenib resistance through NF-kappaB/c-Rel signaling in hepatocellular carcinoma.	Sorafenib	31-40	discoidin domain receptor tyrosine kinase 2	Homo sapiens	17-21	
33969575-5	2021	The effects of DDR2 on Sorafenib resistance were examined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), colony formation, TdT-mediated dUTP nick end labeling (TUNEL), and flow cytometry assays.	Sorafenib	23-32	discoidin domain receptor tyrosine kinase 2	Homo sapiens	15-19	
33969575-7	2021	We demonstrated that DDR2 expression was dramatically upregulated in Sorafenib-resistant HCC tissues relative to sensitive tissues.	Sorafenib	69-78	discoidin domain receptor tyrosine kinase 2	Homo sapiens	21-25	
33969575-8	2021	Downregulation of DDR2 sensitized HCC cell lines to Sorafenib cytotoxicity.	Sorafenib	52-61	discoidin domain receptor tyrosine kinase 2	Homo sapiens	18-22	
33969575-12	2021	Our results demonstrated that DDR2 is a potential therapeutic target in patients with HCC, and targeting DDR2 represents a promising approach to increase Sorafenib sensitivity in patients with HCC.	Sorafenib	154-163	discoidin domain receptor tyrosine kinase 2	Homo sapiens	105-109